A multiinstitutional, concurrent chemoradiation trial of strontium‐89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone

Abstract

The addition of strontium-89 to the regimen of EMP and vinblastine can be delivered safely and in repeated doses, provides effective palliation, and may decrease the need for future radiation therapy. A randomized trial is necessary to quantify these effects.